Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics
about
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataDrug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals.A novel method using confocal laser scanning microscopy for sensitive measurement of P-glycoprotein-mediated transport activity in Caco-2 cells.Pharmacokinetic interaction between losartan and Rhodiola rosea in rabbits.Interactions between herbs and conventional drugs: overview of the clinical data.Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review.Safety surveillance of traditional Chinese medicine: current and futureMining Biomedical Literature to Explore Interactions between Cancer Drugs and Dietary Supplements.Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects.Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study.The effect of Echinacea purpurea on the pharmacokinetics of docetaxel.Cardiovascular effects of noncardiovascular drugs.Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance.Clinically based evidence of drug-herb interactions: a systematic review.Herb-drug pharmacokinetic interactions reviewed.Complementary and alternative medicine therapies in mood disorders.Transporter-mediated drug-drug interactions.An update on the ability of St. John's wort to affect the metabolism of other drugs.Combination therapy of Western drugs and herbal medicines: recent advances in understanding interactions involving metabolism and efflux.Drug interactions with phytotherapeutics in oncology.Current evidence regarding the management of mood and anxiety disorders using complementary and alternative medicine.Functional food red yeast rice (RYR) for metabolic syndrome amelioration: a review on pros and cons.Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.Renal Drug Transporters and Drug Interactions.Effect of quercetin on P-glycoprotein transport ability in Chinese healthy subjects.Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.Clinical risks of St John's Wort (Hypericum perforatum) co-administration.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
P2860
Q27009128-C7BF69DF-AB3A-4807-9182-27ED6823848BQ33509452-6C3A2678-B5F4-452D-A08B-561AA3D496DBQ33947052-396B73C0-FDB7-4789-98C5-E12436E5C175Q34035121-1E379CDE-5F21-4EA2-9B3B-2958C7AA7003Q34124444-7B4D5768-BC5C-4105-A0BC-1FCD7730639BQ34306204-82E110BC-F1EB-47CA-B052-E86EBFDEC308Q35142633-B8460C82-B928-4DF4-832C-E1F931EF3B9CQ35755038-B82800DD-3BBD-473D-AFCA-763C185C7ACCQ36126286-84DE416F-7F16-4964-A218-3B68EB686A41Q36186141-6FADBF01-2674-49EC-A8FA-C88D820655DCQ37161914-2D051776-D21E-4310-AF67-19247F7EFD2BQ37413163-E60F7535-9A1E-4327-BF3B-0407327326D3Q37481442-686E1679-1149-4E14-ABA2-108869CB10F0Q37658866-E75B425A-74BB-41E5-BB44-913FFBDF3BC4Q37808478-14C14BD1-B6BA-4F34-85A4-A0F90A65960EQ37896633-EAE8B995-8C85-470B-AF85-D8F25229F05CQ37905033-3D960136-1484-4948-86E0-FD05C3A76FCDQ38011191-6AF15EF2-5DE0-46C4-9565-32E15AD21F81Q38011807-2C4D1655-4534-4DB6-8866-42BCF316E210Q38175476-9C261E79-4D53-4B5C-8749-56D06410507CQ38193597-A558FE02-7594-44AF-B56D-CA5E8F999A30Q38796540-F930AA66-A6EC-4F49-B753-89712E9A22E8Q38811728-9F1B3A5C-63FA-4168-A075-95AA4EA399BDQ39140289-D4FAA580-CE89-455F-8DDE-A48B4ED01D65Q42688103-8386E510-5188-453E-8474-6C7883DEF45EQ47610956-78B3A00E-09DB-4B5E-8391-9E2FC4E9FD44Q47774682-B79C89DE-ACB0-4861-A458-3CF1EE92931CQ50668713-AC027DAF-4D1F-41B8-A19A-902D0F215D9FQ50854224-4E899B5F-C21E-4767-ACB9-03E8FB1F95E4Q58758044-DE61E48C-6DA7-4859-B3DF-A33AD5E553C2
P2860
Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Gauging the clinical significa ...... in on digoxin pharmacokinetics
@ast
Gauging the clinical significa ...... in on digoxin pharmacokinetics
@en
Gauging the clinical significa ...... in on digoxin pharmacokinetics
@nl
type
label
Gauging the clinical significa ...... in on digoxin pharmacokinetics
@ast
Gauging the clinical significa ...... in on digoxin pharmacokinetics
@en
Gauging the clinical significa ...... in on digoxin pharmacokinetics
@nl
prefLabel
Gauging the clinical significa ...... in on digoxin pharmacokinetics
@ast
Gauging the clinical significa ...... in on digoxin pharmacokinetics
@en
Gauging the clinical significa ...... in on digoxin pharmacokinetics
@nl
P2093
P2860
P921
P356
P1476
Gauging the clinical significa ...... in on digoxin pharmacokinetics
@en
P2093
Ashley Swain
Bill J Gurley
D Keith Williams
Gary Barone
Sunil K Battu
P2860
P356
10.1002/MNFR.200700081
P407
P577
2008-07-01T00:00:00Z